Cabazitaxel is a prescription medicine indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen. It is available as kits. MedsAcross supplies Cabazitaxel for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
JEVTANA ® is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen. JEVTANA is a microtubule inhibitor indicated in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen.
Source: US FDA prescribing information
Cabazitaxel is a microtubule inhibitor. Cabazitaxel binds to tubulin and promotes its assembly into microtubules while simultaneously inhibiting disassembly. This leads to the stabilization of microtubules, which results in the inhibition of mitotic and interphase cellular functions.
Source: US FDA prescribing information
Recommended Dose: JEVTANA 20 mg/m 2 administered every three weeks as a one-hour intravenous infusion in combination with oral prednisone 10 mg administered daily throughout JEVTANA treatment. A dose of 25 mg/m 2 can be used in select patients at the discretion of the treating healthcare provider. JEVTANA requires two dilutions prior to administration. Use the entire contents of the accompanying diluent to achieve a concentration of 10 mg/mL JEVTANA. PVC equipment should not be used. Premedication Regimen: Administer intravenously 30 minutes before each dose of JEVTANA: Antihistamine (dexchlorpheniramine 5 mg or diphenhydramine 25 mg or equivalent antihistamine) Corticosteroid (dexamethasone 8 mg or equivalent steroid) H 2 antagonist. Antiemetic prophylaxis (oral or intravenous) is recommended as needed. Dosage Modifications: See full prescribing information
Source: US FDA prescribing information
JEVTANA is contraindicated in patients with: neutrophil counts of ≤1,500/mm 3 history of severe hypersensitivity reactions to cabazitaxel or to other drugs formulated with polysorbate 80 severe hepatic impairment (total bilirubin >3 × ULN) Neutrophil counts of ≤1,500/mm 3. History of severe hypersensitivity to JEVTANA or polysorbate 80. Severe hepatic impairment (Total Bilirubin >3 × ULN)
Source: US FDA prescribing information
Boxed warning (neutropenia and hypersensitivity warning: neutropenia and hypersensitivity): Neutropenic deaths have been reported. Obtain frequent blood counts to monitor for neutropenia. JEVTANA is contraindicated in patients with neutrophil counts of ≤1,500 cells/mm 3. Primary prophylaxis with G-CSF is recommended in patients with high-risk clinical features. Consider primary prophylaxis with G-CSF in all patients receiving a dose of 25 mg/m 2. Bone marrow suppression (particularly neutropenia) and its clinical consequences (febrile neutropenia, neutropenic infections, and death): Monitor blood counts frequently to determine if dosage modification or initiation of G-CSF is needed. Closely monitor patients with hemoglobin <10 g/dL.
Source: US FDA prescribing information
The following serious adverse reactions are discussed in greater detail in another section of the label: Bone Marrow Suppression Increased Toxicities in Elderly Patients Hypersensitivity Reactions Gastrointestinal Adverse Reactions Renal Failure Urinary Disorders Including Cystitis Respiratory Disorders Use in Patients with Hepatic Impairment Most common all grades adverse reactions and laboratory abnormalities (≥10%) with JEVTANA 20 mg/m 2 or 25 mg/m 2 are neutropenia, anemia, diarrhea, nausea, fatigue, asthenia, vomiting, hematuria, constipation, decreased appetite, back pain, and abdominal pain.
Source: US FDA prescribing information
Avoid coadministration of JEVTANA with strong CYP3A inhibitors. If patients require coadministration of a strong CYP3A inhibitor, consider a 25% JEVTANA dose reduction.
Source: US FDA prescribing information
Store at 25°C (77°F), excursions permitted between 15°C–30°C (59°F–86°F). Do not refrigerate.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Cabazitaxel, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Jevtana kit | Sanofi-Aventis | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Cabazitaxel in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 1 presentations of Cabazitaxel and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Cabazitaxel, including Jevtana.
Yes. The US FDA first approved Cabazitaxel on 17 June 2010, according to Drugs@FDA.
Yes. Cabazitaxel has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Cabazitaxel is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Cabazitaxel is classified under ATC code L01CD04 (Cabazitaxel).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.